A Phase 2 interventional study of RE-021 (Sparsentan) and Irbesartan in Focal Segmental Glomerulosclerosis, sponsored by Travere Therapeutics, Inc.. Completed at 33 sites in 3 countries. Open to participants aged 8 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Travere Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 6th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2014, is one of 29 in phase 2, and was the 23rd registered.
106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.
Browse Glomerulosclerosis, Focal Segmental studies →18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 34 more countries
Ages 12+
Akebia Therapeutics · Sites in United States
Ages 18+
Meyer Children's Hospital IRCCS · Sites in United States, Germany, Italy and 2 more countries
Ages 0–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.
This study: 8 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 31 · Phase 3 5 · Phase 4 4
First in 1996; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 30 across 73 interventional studies indexed under Glomerulosclerosis, Focal Segmental.
Median enrollment 30 across the 56 interventional studies, 252 across the 13 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 69 have an industry lead sponsor. The 10 most frequent:
Travere Therapeutics, Inc. is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Travere Therapeutics, Inc. has 6 studies filed under Glomerulosclerosis, Focal Segmental — fewer than ten, so there is no comparison to draw.
10 of the studies in Glomerulosclerosis, Focal Segmental with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01094327University of MiamiProteinuria in Pre and Post Transplant | 2026-11-30 |
| NCT06500702SanofiA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | 2026-12-23 |
| NCT07219121Travere Therapeutics, Inc.Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | 2027-03 |
| NCT05583942Northwell HealthA Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) | 2027-03-01 |
| NCT05588063Northwell HealthtaVNS for FRNS in Children | 2027-03-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
Focal segmental glomerulosclerosis (FSGS) is a rare glomerular disorder which results in frank proteinuria and in some patients progression to end-stage kidney disease (ESKD) over 5-10 years. Proteinuria reduction is widely regarded to be beneficial and is considered the primary goal of treatment in FSGS and slowing its progressive course (D'Agati, et. al, 2011). Patients are currently treated with angiotensin receptor blockers (ARB) and angiotensin converting inhibitors (ACEI) to lower proteinuria with steroids, calcineurin inhibitors, and other immunosuppressive agents reserved for patients with severe proteinuria and in particular with nephrotic syndrome. Despite these therapies, many patients have nephrotic range proteinuria and new therapeutic agents are needed. Endothelin receptor antagonists (ERA) have been shown to lower proteinuria in clinical trials of diabetic nephropathy and have been speculated to be effective in FSGS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Patients >18 years of age with Estimated (eGFR) ≥60 ml mL/min who have N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥200 pg/mL (57.8 pmol/L). For patients >18 years of age with eGFR \<60 mL/min, the following parameters requiring echocardiography (ECHO) at screening should be used for exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg. Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration.
Drug: RE-021 (Sparsentan)
RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg. Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration.
Drug: RE-021 (Sparsentan)
RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg. Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration.
Drug: RE-021 (Sparsentan)
The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks. Patients at \</= 50kg will receive 150mg irbesartan for the 8 week duration.
Drug: Irbesartan
Includes all subjects who completed the Double-Blind period and enrolled in the Open-Label Extension period of the study. All subjects who completed the Double-Blind period were evaluated for response and safety at the Week 8 visit to determine eligibility for continued treatment on their assigned doses in an Open-Label Extension period for up to 496 additional weeks. Subjects treated with irbesartan during the Double-Blind period were offered sparsentan treatment at the dose they would have received according to the Double-Blind dose cohort in which they were enrolled.
Drug: RE-021 (Sparsentan)
Oral, once-daily
Also known as: Sparsentan
Oral, once-daily
Also known as: Avapro
Percent Change in Urine Protein/Creatinine (Up/C)
Primary efficacy objective is to determine the change in UP/C in FSGS patients receiving RE-021 (Sparsentan) from baseline to 8 weeks over a range of dose levels compared to treatment with irbesartan as active control.
Time frame: 8 weeks
Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE)
The secondary efficacy endpoint is the proportion of FSGS patients achieving FPRE (experiencing a UP/C ratio ≤1.5 g/g and \>40% reduction from baseline in Up/C) at Week 8 over a range of dose levels compared to treatment with irbesartan as active control.
Time frame: 8 weeks
| Milestone | RE-021 (Sparsentan) 200 mg - Double-Blind Period | RE-021 (Sparsentan) 400 mg - Double-Blind Period | RE-021 (Sparsentan) 800 mg - Double-Blind Period | Irbesartan 300 mg - Double-Blind Period | RE-021 (Sparsentan) - Open-Label Extension Period |
|---|---|---|---|---|---|
| Started | 13 | 26 | 34 | 36 | 0 |
| Completed | 13 | 23 | 32 | 35 | 0 |
| Not completed | 0 | 3 | 2 | 1 | 0 |
| Milestone | RE-021 (Sparsentan) 200 mg - Double-Blind Period | RE-021 (Sparsentan) 400 mg - Double-Blind Period | RE-021 (Sparsentan) 800 mg - Double-Blind Period | Irbesartan 300 mg - Double-Blind Period | RE-021 (Sparsentan) - Open-Label Extension Period |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 103 |
| Active at study end | 0 | 0 | 0 | 0 | 30 |
| Completed | 0 | 0 | 0 | 0 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 102 |
Primary efficacy objective is to determine the change in UP/C in FSGS patients receiving RE-021 (Sparsentan) from baseline to 8 weeks over a range of dose levels compared to treatment with irbesartan as active control.
| percent change | RE-021 (Sparsentan) 200, 400, 800 mg Pooled | Irbesartan 300 mg Pooled | RE-021 (Sparsentan) 400 and 800 mg Pooled | RE-021 (Sparsentan) 200mg | RE-021 (Sparsentan) 400mg | RE-021 (Sparsentan) 800mg |
|---|---|---|---|---|---|---|
| Percent Change in Urine Protein/Creatinine (Up/C) | -44.8 (-52.7 to -35.7) | -18.5 (-34.6 to 1.7) | -47.4 (-56.3 to -36.9) | -33.1 (-49.3 to -11.6) | -52.7 (-64.3 to -37.2) | -41.3 (-54.4 to -24.4) |
The secondary efficacy endpoint is the proportion of FSGS patients achieving FPRE (experiencing a UP/C ratio ≤1.5 g/g and \>40% reduction from baseline in Up/C) at Week 8 over a range of dose levels compared to treatment with irbesartan as active control.
| percentage of patients | RE-021 (Sparsentan) 200, 400, 800 mg Pooled | Irbesartan 300 mg Pooled | RE-021 (Sparsentan) 400 and 800 mg Pooled | RE-021 (Sparsentan) 200 mg | RE-021 (Sparsentan) 400 mg | RE-021 (Sparsentan) 800 mg |
|---|---|---|---|---|---|---|
| Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE) | 28.13 | 9.38 | 31.37 | 15.38 | 38.10 | 26.67 |
Collected over For double-blind treatment arms: 8 weeks. For all sparsentan analysis including the open-label extension period: up to 508 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RE-021 (Sparsentan) 200 mg - Double-Blind Period | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| RE-021 (Sparsentan) 400 mg - Double-Blind Period | 0/26 (0%) | 0/26 (0%) | 17/26 (65.4%) |
| RE-021 (Sparsentan) 800 mg - Double-Blind Period | 0/34 (0%) | 2/34 (5.9%) | 27/34 (79.4%) |
| Irbesartan 300 mg - Double-Blind Period | 0/36 (0%) | 1/36 (2.8%) | 26/36 (72.2%) |
| All Sparsentan (Double-Blind and Open-Label Extension) | 0/108 (0%) | 48/108 (44.4%) | 104/108 (96.3%) |
| Event | RE-021 (Sparsentan) 200 mg - Double-Blind Period | RE-021 (Sparsentan) 400 mg - Double-Blind Period | RE-021 (Sparsentan) 800 mg - Double-Blind Period | Irbesartan 300 mg - Double-Blind Period | All Sparsentan (Double-Blind and Open-Label Extension) |
|---|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/13 | 0/26 | 0/34 | 0/36 | 10/108 |
| COVID-19Infections and infestations | 0/13 | 0/26 | 0/34 | 0/36 | 10/108 |
| PneumoniaInfections and infestations | 0/13 | 0/26 | 0/34 | 0/36 | 4/108 |
| Chest painGeneral disorders | 0/13 | 0/26 | 0/34 | 0/36 | 4/108 |
| Drug withdrawal syndromeGeneral disorders | 0/13 | 0/26 | 1/34 | 0/36 | 1/108 |
| Sinus bradycardiaCardiac disorders | 0/13 | 0/26 | 1/34 | 0/36 | 1/108 |
| SyncopeNervous system disorders | 0/13 | 0/26 | 1/34 | 0/36 | 3/108 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/13 | 0/26 | 1/34 | 0/36 | 1/108 |
| Pulse absentInvestigations | 0/13 | 0/26 | 1/34 | 0/36 | 1/108 |
| ProteinuriaRenal and urinary disorders | 0/13 | 0/26 | 0/34 | 0/36 | 3/108 |
| Event | RE-021 (Sparsentan) 200 mg - Double-Blind Period | RE-021 (Sparsentan) 400 mg - Double-Blind Period | RE-021 (Sparsentan) 800 mg - Double-Blind Period | Irbesartan 300 mg - Double-Blind Period | All Sparsentan (Double-Blind and Open-Label Extension) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/13 | 2/26 | 9/34 | 7/36 | 32/108 |
| Oedema peripheralGeneral disorders | 1/13 | 2/26 | 2/34 | 1/36 | 30/108 |
| DiarrhoeaGastrointestinal disorders | 1/13 | 1/26 | 4/34 | 1/36 | 27/108 |
| NauseaGastrointestinal disorders | 1/13 | 3/26 | 5/34 | 3/36 | 26/108 |
| HypotensionVascular disorders | 1/13 | 3/26 | 6/34 | 3/36 | 23/108 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/13 | 0/26 | 0/34 | 2/36 | 22/108 |
| DizzinessNervous system disorders | 0/13 | 4/26 | 6/34 | 4/36 | 19/108 |
| VomitingGastrointestinal disorders | 0/13 | 3/26 | 3/34 | 1/36 | 19/108 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/13 | 0/26 | 0/34 | 1/36 | 19/108 |
| HypertensionVascular disorders | 0/13 | 0/26 | 0/34 | 1/36 | 19/108 |
| Age, Continuous(years) | RE-021 (Sparsentan) 200 mg - Double-Blind Period | RE-021 (Sparsentan) 400 mg - Double-Blind Period | RE-021 (Sparsentan) 800 mg - Double-Blind Period | Irbesartan 300 mg - Double-Blind Period | Total |
|---|---|---|---|---|---|
| Mean | 42.8 ± 14.36 | 38.3 ± 16.78 | 35.9 ± 17.68 | 34.1 ± 15.96 | 36.7 ± 16.54 |
| Sex: Female, Male(Participants) | RE-021 (Sparsentan) 200 mg - Double-Blind Period | RE-021 (Sparsentan) 400 mg - Double-Blind Period | RE-021 (Sparsentan) 800 mg - Double-Blind Period | Irbesartan 300 mg - Double-Blind Period | Total |
|---|---|---|---|---|---|
| Female | 6 | 9 | 17 | 17 | 49 |
| Male | 7 | 17 | 17 | 19 | 60 |
Ran from Mar 2014 to primary completion in Jun 2016, 27 months.
Results were first posted in Jul 2021, 5 years 1 month after primary completion.
Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sparsentan
Glomerulosclerosis, Focal Segmental →
Travere Therapeutics, Inc.